Rondo Therapeutics
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
San Francisco, California, United StatesWebsite
www.rondotx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About Rondo Therapeutics
Rondo Therapeutics is a clinical-stage biotechnology company focused on advancing immuno-oncology treatments for solid tumors that are resistant to existing therapies. They specialize in developing immune-cell engaging bispecific antibodies designed to maximize efficacy while minimizing side effects. The company employs a rapid discovery approach to create a multi-product pipeline of therapeutics aimed at delivering durable responses for patients. Led by experienced founders, Rondo Therapeutics is backed by a strong investor syndicate and strategic partnerships to enhance their clinical programs.Explore more
Rondo Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Rondo Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Rondo Therapeutics has new funding data
Earning: See what the market has to say on Rondo Therapeutics recently announced quarterly report
Click to see if Rondo Therapeutics had a recent Job posting/layoffs
Check out if Rondo Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Rondo Therapeutics
Website visits: Recent activity has been detected on your website
Rondo Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Rondo Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Rondo Therapeutics launches new products
Recommended Actions
Reach out to Masked Content who joined Rondo Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Rondo Therapeutics
Compare insights from companies similar to Rondo Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Rondo Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Rondo Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Rondo Therapeutics.
Rondo Therapeutics financials insights
Gather financial insights about Rondo Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$67M
Rondo Therapeutics Tech Stack
A closer look at the technologies used by Rondo Therapeutics
See more technologies
Most Recent Scoops
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Event
Events, Engineering, Research & Development, Training, Machine Learning, Learning & Development, Search, Laboratory Operations, Medical Education & Training, Medical Research, Chemical Engineering, Artificial Intelligence, Clinical Operations, Healthcare Technology, HR Operations, Operations
Rondo Therapeutics News & Media
Rondo Therapeutics Presents Preclinical Data at ASCO GU for its Novel CD28 x Nectin-4 Costimulatory Bispecific Antibody for Advanced Bladder Cancer
HAYWARD, Calif.--(BUSINESS WIRE)--Rondo Therapeutics, a privately held biopharmaceutical immuno-oncology company pioneering the development of next-generation T cell-engaging bispecific antibodies for the treatment of solid tumors, today announced that data from preclinical studies of RNDO-564, a novel CD28 x Nectin-4 costimulatory bispecific antibody for advanced bladder cancer, is being presented in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) CRondo Therapeutics Announces Collaboration with Lilly to Develop Novel CD28 Bispecific Antibodies for Solid Tumors
HAYWARD, Calif.--(BUSINESS WIRE)--Rondo Therapeutics, a privately held biopharmaceutical immuno-oncology company pioneering the development of next-generation T cell-engaging bispecific antibodies for the treatment of solid tumors, today announced a research collaboration and license agreement with Eli Lilly and Company. This collaboration will combine Rondo Therapeutics’ proprietary CD28 co-stimulatory platform with Lilly’s drug development and commercialization expertise to develop co-stimulaThomas Manley, M.D. Joins Rondo Therapeutics as Chief Medical Officer to Lead Clinical Development of Rondo Therapeutics’ Bispecific Antibody Programs
HAYWARD, Calif.--(BUSINESS WIRE)--Rondo Therapeutics, a private biopharmaceutical company pioneering next-generation bispecific antibody platforms, has named Thomas Manley, M.D., as Chief Medical Officer (CMO). Dr. Manley will lead the clinical development of Rondo's innovative T-cell engaging immunotherapies designed to treat solid tumors, including metastatic bladder and ovarian cancers. With more than 25 years in oncology research and development, Dr. Manley brings expertise from both leadinSteven James, Accomplished CEO and Biotech Executive, Joins Board of Directors of Rondo Therapeutics
HAYWARD, Calif.--(BUSINESS WIRE)--Rondo Therapeutics, a privately-held biopharmaceutical company advancing next-generation immuno-oncology platforms, announces the appointment of Steven James to its Board of Directors. Mr. James brings over three decades of biopharmaceutical experience to Rondo’s Board of Directors. He was instrumental in building and leading several companies into the clinic, resulting in $2B+ in M&A value for stakeholders. Mr. James’ addition to the Board of Directors str
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Rondo Therapeutics
Sign Up For FreeTo access detailed company insights
Rondo Therapeutics is a clinical-stage biotechnology company focused on advancing immuno-oncology treatments for solid tumors that are resistant to existing therapies. They specialize in developing immune-cell engaging bispecific antibodies designed to maximize efficacy while minimizing side effects. The company employs a rapid discovery approach t... Read More
